Sionna Therapeutics (NASDAQ:SION) Now Covered by Analysts at Lifesci Capital

Lifesci Capital assumed coverage on shares of Sionna Therapeutics (NASDAQ:SION) in a report released on Tuesday,Benzinga reports. The firm issued an outperform rating and a $60.00 price objective on the stock.

Several other research firms have also weighed in on SION. Jones Trading initiated coverage on shares of Sionna Therapeutics in a research note on Monday, September 8th. They issued a “buy” rating and a $46.00 price objective for the company. Royal Bank Of Canada reaffirmed an “underperform” rating and issued a $24.00 price target on shares of Sionna Therapeutics in a research note on Monday, December 1st. Weiss Ratings reiterated a “sell (e+)” rating on shares of Sionna Therapeutics in a report on Monday, December 15th. BTIG Research started coverage on shares of Sionna Therapeutics in a research report on Wednesday, November 19th. They set a “buy” rating and a $50.00 price objective on the stock. Finally, Raymond James Financial reaffirmed a “strong-buy” rating on shares of Sionna Therapeutics in a research report on Wednesday, November 5th. Two investment analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Sionna Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $43.14.

Sionna Therapeutics Trading Up 2.4%

NASDAQ SION opened at $43.44 on Tuesday. The firm has a market capitalization of $1.94 billion and a PE ratio of -8.92. The business’s 50-day moving average price is $39.33 and its two-hundred day moving average price is $27.79. Sionna Therapeutics has a 12 month low of $7.26 and a 12 month high of $45.00.

Sionna Therapeutics (NASDAQ:SION) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($0.46) earnings per share for the quarter, topping the consensus estimate of ($0.52) by $0.06.

Insider Transactions at Sionna Therapeutics

In other Sionna Therapeutics news, CEO Michael Cloonan sold 99,800 shares of the business’s stock in a transaction on Tuesday, October 21st. The stock was sold at an average price of $36.26, for a total value of $3,618,748.00. Following the transaction, the chief executive officer owned 547,343 shares of the company’s stock, valued at approximately $19,846,657.18. The trade was a 15.42% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Ra Capital Management, L.P. sold 311,000 shares of the company’s stock in a transaction on Friday, October 24th. The shares were sold at an average price of $39.50, for a total value of $12,284,500.00. Following the completion of the transaction, the director owned 219,867 shares of the company’s stock, valued at $8,684,746.50. This trade represents a 58.58% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 1,608,591 shares of company stock worth $58,478,956. 3.90% of the stock is owned by insiders.

Institutional Trading of Sionna Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Charles Schwab Investment Management Inc. purchased a new position in Sionna Therapeutics in the first quarter valued at about $676,000. Siren L.L.C. purchased a new position in Sionna Therapeutics in the first quarter valued at approximately $3,400,000. Driehaus Capital Management LLC purchased a new position in Sionna Therapeutics in the first quarter valued at approximately $3,440,000. TPG GP A LLC bought a new position in Sionna Therapeutics during the first quarter valued at $69,925,000. Finally, Baker BROS. Advisors LP purchased a new stake in Sionna Therapeutics in the first quarter worth $4,184,000.

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.